Literature DB >> 25122198

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Jared M Lucas1, Cynthia Heinlein1, Tom Kim1, Susana A Hernandez1, Muzdah S Malik1, Lawrence D True2, Colm Morrissey3, Eva Corey3, Bruce Montgomery4, Elahe Mostaghel5, Nigel Clegg1, Ilsa Coleman1, Christopher M Brown6, Eric L Schneider6, Charles Craik6, Julian A Simon1, Antonio Bedalov1, Peter S Nelson7.   

Abstract

UNLABELLED: TMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastases. Through the generation of mouse models with a targeted deletion of Tmprss2, we demonstrate that the activity of this protease regulates cancer cell invasion and metastasis to distant organs. By screening combinatorial peptide libraries, we identified a spectrum of TMPRSS2 substrates that include pro-hepatocyte growth factor (HGF). HGF activated by TMPRSS2 promoted c-MET receptor tyrosine kinase signaling, and initiated a proinvasive epithelial-to-mesenchymal transition phenotype. Chemical library screens identified a potent bioavailable TMPRSS2 inhibitor that suppressed prostate cancer metastasis in vivo. Together, these findings provide a mechanistic link between androgen-regulated signaling programs and prostate cancer metastasis that operate via context-dependent interactions with extracellular constituents of the tumor microenvironment. SIGNIFICANCE: The vast majority of prostate cancer deaths are due to metastasis. Loss of TMPRSS2 activity dramatically attenuated the metastatic phenotype through mechanisms involving the HGF-c-MET axis. Therapeutic approaches directed toward inhibiting TMPRSS2 may reduce the incidence or progression of metastasis in patients with prostate cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25122198      PMCID: PMC4409786          DOI: 10.1158/2159-8290.CD-13-1010

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  49 in total

Review 1.  Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes.

Authors:  J D Hooper; J A Clements; J P Quigley; T M Antalis
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin.

Authors:  B J Backes; J L Harris; F Leonetti; C S Craik; J A Ellman
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

3.  High expression of the Met receptor in prostate cancer metastasis to bone.

Authors:  Beatrice S Knudsen; Glenn A Gmyrek; Jennifer Inra; Douglas S Scherr; E Darracott Vaughan; David M Nanus; Michael W Kattan; William L Gerald; George F Vande Woude
Journal:  Urology       Date:  2002-12       Impact factor: 2.649

4.  Expression profiling reveals hepsin overexpression in prostate cancer.

Authors:  J A Magee; T Araki; S Patil; T Ehrig; L True; P A Humphrey; W J Catalona; M A Watson; J Milbrandt
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

5.  Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.

Authors:  Eva Corey; Janna E Quinn; Franck Bladou; Lisha G Brown; Martine P Roudier; Julie M Brown; Kent R Buhler; Robert L Vessella
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

6.  Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.

Authors:  G A Gmyrek; M Walburg; C P Webb; H M Yu; X You; E D Vaughan; G F Vande Woude; B S Knudsen
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

8.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries.

Authors:  J L Harris; B J Backes; F Leonetti; S Mahrus; J A Ellman; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

9.  Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Authors:  Paula J Kaplan-Lefko; Tsuey-Ming Chen; Michael M Ittmann; Roberto J Barrios; Gustavo E Ayala; Wendy J Huss; Lisette A Maddison; Barbara A Foster; Norman M Greenberg
Journal:  Prostate       Date:  2003-05-15       Impact factor: 4.104

Review 10.  Molecular basis of metastasis.

Authors:  Anne C Chiang; Joan Massagué
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

View more
  163 in total

1.  Insights into the mechanism of organ-specific cancer metastasis.

Authors:  Mark A Rubin
Journal:  Cancer Discov       Date:  2014-11       Impact factor: 39.397

Review 2.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

3.  Grainyhead-like 2 downstream targets act to suppress epithelial-to-mesenchymal transition during neural tube closure.

Authors:  Heather J Ray; Lee A Niswander
Journal:  Development       Date:  2016-02-22       Impact factor: 6.868

4.  DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Authors:  Jonathan F Goodwin; Vishal Kothari; Justin M Drake; Shuang Zhao; Emanuela Dylgjeri; Jeffry L Dean; Matthew J Schiewer; Christopher McNair; Jennifer K Jones; Alvaro Aytes; Michael S Magee; Adam E Snook; Ziqi Zhu; Robert B Den; Ruth C Birbe; Leonard G Gomella; Nicholas A Graham; Ajay A Vashisht; James A Wohlschlegel; Thomas G Graeber; R Jeffrey Karnes; Mandeep Takhar; Elai Davicioni; Scott A Tomlins; Cory Abate-Shen; Nima Sharifi; Owen N Witte; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

Review 5.  Translational and clinical implications of the genetic landscape of prostate cancer.

Authors:  Daniel E Spratt; Zachary S Zumsteg; Felix Y Feng; Scott A Tomlins
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

6.  Prostate cancer: TMPRSS2 promotes metastasis through proteolysis.

Authors:  Robert Phillips
Journal:  Nat Rev Urol       Date:  2014-09-02       Impact factor: 14.432

7.  Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.

Authors:  Shao-Chun Wang; Yeh Chen; Yu-Chuan Wang; Wei-Jan Wang; Chia-Shin Yang; Chia-Ling Tsai; Mei-Hui Hou; Hsiao-Fan Chen; Yi-Chun Shen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 8.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

9.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.